SCHEMBL1787346

SCHEMBL1787346

O=C(NCc1ccc2c(c1)CCN(C1=CC=C1)CC2)c1ccnnc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.41
LMNA P02545 7/20 0.40
TP53 P04637 5/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PREP P48147 1/20 0.38
PRKAB2 O43741 1/20 0.38
PRKAG1 P54619 1/20 0.38
PRKAA2 P54646 1/20 0.38
PRKAA1 Q13131 1/20 0.38
PRKAG3 Q9UGI9 1/20 0.38
PRKAG2 Q9UGJ0 1/20 0.38
PRKAB1 Q9Y478 1/20 0.38
ROCK2 O75116 1/20 0.37
THRB P10828 1/20 0.37
HSD17B10 Q99714 1/20 0.36
HPGD P15428 1/20 0.36
IDO1 P14902 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1790517 0.89 LMNA (0.51) MAPK14LMNATP53POLBSMN1; SMN2
SCHEMBL1789763 0.84 TP53 (0.41) MAPK14LMNATP53POLBROCK2
SCHEMBL1788052 0.84 TP53 (0.44) MAPK14LMNATP53POLBPRKAB2
SCHEMBL1787198 0.83 PRKAB2 (0.41) MAPK14LMNATP53POLBPRKAB2
SCHEMBL1789875 0.82 TP53 (0.44) MAPK14LMNATP53THRBHPGD
SCHEMBL1789792 0.82 LMNA (0.50) MAPK14LMNATP53SMN1; SMN2THRB
SCHEMBL1788622 0.82 DGAT2 (0.42) MAPK14TP53SMN1; SMN2PRKAB2PRKAG1
SCHEMBL1788306 0.81 LMNA (0.43) MAPK14LMNATP53POLBPRKAB2
SCHEMBL1787185 0.81 PRKAB2 (0.42) MAPK14LMNATP53POLBPRKAB2
SCHEMBL1789862 0.81 SMN1; SMN2 (0.50) TP53POLBSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326625-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2011-06-01 EP disclosed
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
WO-2010007382-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS HRH4, HRH3, HRH2 MAPK14 2341/4885LMNA 2172/4885TP53 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.